CareDx Stock Forecast, Price & News

-1.53 (-1.65 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume627,056 shs
Average Volume625,234 shs
Market Capitalization$4.75 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CareDx logo

About CareDx

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.97 out of 5 stars

Medical Sector

1152nd out of 2,099 stocks

Medical Laboratories Industry

21st out of 40 stocks

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

CareDx (NASDAQ:CDNA) Frequently Asked Questions

Is CareDx a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CareDx stock.
View analyst ratings for CareDx
or view top-rated stocks.

What stocks does MarketBeat like better than CareDx?

Wall Street analysts have given CareDx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CareDx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CareDx's next earnings date?

CareDx is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for CareDx

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) posted its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.13. The firm earned $67.40 million during the quarter, compared to analysts' expectations of $60.77 million. CareDx had a negative trailing twelve-month return on equity of 4.25% and a negative net margin of 6.14%.
View CareDx's earnings history

How has CareDx's stock been impacted by Coronavirus (COVID-19)?

CareDx's stock was trading at $18.94 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDNA shares have increased by 381.8% and is now trading at $91.25.
View which stocks have been most impacted by COVID-19

What guidance has CareDx issued on next quarter's earnings?

CareDx updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $270 million-$280 million, compared to the consensus revenue estimate of $260.92 million.

What price target have analysts set for CDNA?

7 brokerages have issued twelve-month target prices for CareDx's shares. Their forecasts range from $35.00 to $100.00. On average, they anticipate CareDx's share price to reach $78.43 in the next year. This suggests that the stock has a possible downside of 14.1%.
View analysts' price targets for CareDx
or view top-rated stocks among Wall Street analysts.

Who are CareDx's key executives?

CareDx's management team includes the following people:
  • Dr. Peter Maag, Exec. Chairman (Age 54, Pay $1.35M)
  • Dr. Reginald Seeto, Pres, CEO & Director (Age 49, Pay $989.04k)
  • Ms. Sasha King M.B.A., Chief Marketing Officer (Age 35, Pay $668.8k)
  • Mr. Marcel Konrad, VP & Corp. Controller (Age 45, Pay $437.53k)
  • Mr. Ankur Dhingra, Chief Financial Officer (Age 45)
  • Mr. Paul Ciccolella, Sr. VP of Global Operations
  • Mr. Amitabh Shukla, Sr. VP of Technology
  • Mr. Martyn Edney, Sr. VP of HR
  • Dr. Sham Dholakia DPHIL, M.D., Sr. VP of Medical Affairs & Clinical Operations
  • Mr. Kashif Rathore, Sr. VP of Digital Bus.

Who are some of CareDx's key competitors?

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Square (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

Who are CareDx's major shareholders?

CareDx's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (8.57%), Fred Alger Management LLC (7.89%), BlackRock Inc. (7.88%), Waddell & Reed Financial Inc. (2.93%), Clearbridge Investments LLC (2.90%) and Matrix Capital Management Company LP (2.76%). Company insiders that own CareDx stock include George Bickerstaff, James P Yee, Michael Brian Bell, Michael Goldberg, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King and William A Hagstrom.
View institutional ownership trends for CareDx

Which institutional investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Price T Rowe Associates Inc. MD, First Light Asset Management LLC, Gagnon Securities LLC, Waddell & Reed Financial Inc., Royce & Associates LP, Bellevue Group AG, and Federated Hermes Inc.. Company insiders that have sold CareDx company stock in the last year include George Bickerstaff, Michael Brian Bell, Michael Goldberg, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, and William A Hagstrom.
View insider buying and selling activity for CareDx
or view top insider-selling stocks.

Which institutional investors are buying CareDx stock?

CDNA stock was purchased by a variety of institutional investors in the last quarter, including Matrix Capital Management Company LP, Clearbridge Investments LLC, ARK Investment Management LLC, BlackRock Inc., Goldman Sachs Group Inc., Lord Abbett & CO. LLC, Azimuth Capital Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for CareDx
or or view top insider-buying stocks.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $91.25.

How much money does CareDx make?

CareDx has a market capitalization of $4.75 billion and generates $192.19 million in revenue each year. The company earns $-18,710,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does CareDx have?

CareDx employs 456 workers across the globe.

What is CareDx's official website?

The official website for CareDx is

Where are CareDx's headquarters?

CareDx is headquartered at 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080.

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-287-2300 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.